Roche bets on obesity trump card

Posted 13 March 2025 PM

Roche has shored up its obesity portfolio by partnering with Zealand Pharma for a much-hyped amylin analog in Phase 2 trials in a deal worth up to AU$8.3 billion.

Zealand announced last August that it was looking for a partner for petrelintide, which has a different mechanism of action than the GLP-1 RAs dominating the market. The pharma said it has weight loss results similar to GLP-1 RAs but with a better tolerability profile.

To see the whole article, please login